Core Points - The major shareholders of Gongdong Medical have reduced their holdings, with the controlling shareholder Shi Huiyong decreasing his stake from 50.27% to 48.27% and Jinchi Investment reducing from 6.47% to 5.47% [1] - The total amount of shares reduced by Shi Huiyong is 4,402,400 shares, while Jinchi Investment has reduced 2,204,840 shares, resulting in a combined reduction of approximately 11.92 million yuan [1] - Shi Huiyong and Jinchi Investment have cumulatively cashed out approximately 12.39 million yuan from their holdings [3] Shareholder Details - Shi Huiyong and Shi Yibei are father and daughter, with Shi Huiyong being the general partner and executive partner of Jinchi Investment [2] - Together, Shi Huiyong, Shi Yibei, and Jinchi Investment hold a total of 141,558,049 shares, representing 64.21% of the company's total equity [2] - Jinchi Investment is an employee stock ownership platform, and Shi Huiyong did not participate in the recent reduction of shares by Jinchi Investment [2] Historical Context - Shi Huiyong initially held 42 million shares, which was 52.50% of the total equity, and has cumulatively reduced 3,151,400 shares since July 26, 2024, cashing out approximately 8.04 million yuan [2] - Jinchi Investment initially held 6 million shares, or 7.50% of the total equity, and has cumulatively reduced 1,575,700 shares since March 11, 2025, cashing out approximately 4.36 million yuan [2]

Core Viewpoint - The announcement details the share reduction by major shareholders of Zhejiang Gongdong Medical Instrument Co., Ltd., including the results of the reduction and changes in equity ownership [1][10]. Group 1: Shareholder and Ownership Information - The controlling shareholder, Shi Huiyong, held 110,836,040 shares, representing 50.27% of the total share capital before the reduction. Taizhou Jinch Investment Management Partnership held 14,258,009 shares, accounting for 6.47% [2]. - After the reduction, Shi Huiyong holds 106,433,640 shares (48.27%), while Jinch Investment holds 12,053,169 shares (5.47%) [3]. Group 2: Reduction Plan Implementation Results - The reduction plan was announced on September 5, 2025, allowing Shi Huiyong to reduce up to 4,409,858 shares and Jinch Investment to reduce up to 2,204,929 shares within the specified period from September 26 to December 24, 2025 [3][8]. - By December 16, 2025, Shi Huiyong had reduced 4,402,400 shares, and Jinch Investment had reduced 2,204,840 shares, completing the reduction plan [3][11]. Group 3: Equity Change Details - The equity change occurred between October 31 and December 16, 2025, with Shi Huiyong and Jinch Investment's combined shareholding decreasing from 141,017,809 shares (63.96%) to 134,950,809 shares (61.21%) [9]. - The reduction did not trigger a mandatory tender offer and will not significantly impact the company's governance structure or ongoing operations [10].

Group 1 - The core point of the article is that Gongdong Medical conducted a block trade on December 16, with a total transaction volume of 4.4024 million shares and a transaction amount of 76.2056 million yuan, at an average price of 17.31 yuan, reflecting a discount of 5.46% compared to the closing price of the day [1] Group 2 - The block trade details include six transactions, with the largest single transaction being 1 million shares at a price of 17.31 yuan, executed by institutional buyers through Zheshang Securities [1] - The total transaction volume and amount indicate significant trading activity, suggesting potential interest from institutional investors in Gongdong Medical [1]

证券代码：605369 证券简称：拱东医疗 公告编号：2025-036 浙江拱东医疗器械股份有限公司 股东减持股份结果暨权益变动触及 1%刻度公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 大股东及董监高持股的基本情况 本次减持计划实施前，公司控股股东、实际控制人施慧勇持有公司股份 110,836,040 股，占公司总股本的 50.27%。台州金驰投资管理合伙企业（有限合 伙）（以下简称"金驰投资"）持有浙江拱东医疗器械股份有限公司（以下简称"公 司"、"拱东医疗"）股份 14,258,009 股，占公司总股本的 6.47%。 减持计划的实施结果情况 2025年9月5日，公司披露了《股东减持股份计划公告》（公告编号：2025-029）， 自公告披露之日起 15 个交易日后的 3 个月内（即减持区间为：2025 年 9 月 26 日至 2025 年 12 月 24 日），公司控股股东、实际控制人施慧勇拟通过大宗交易 方式合计减持数量不超过 4,409,858 股，且在任意连续 90 日内，减持股份 ...

Core Viewpoint - Gongdong Medical (605369.SH) announced the completion of share reduction plans by key stakeholders, indicating potential changes in ownership structure and investor sentiment [1] Share Reduction Details - Mr. Shi Huiyong has reduced his holdings by 4.4024 million shares through block trading, while Jinch Investment has reduced its holdings by 2.2048 million shares through centralized bidding [1] - After the completion of the reduction plan, Mr. Shi holds 106 million shares, representing 48.27% of the company's total share capital, while Jinch Investment holds 12.0532 million shares, accounting for 5.47% of the total share capital [1]

Core Viewpoint - Gongdong Medical (605369.SH) announced the completion of share reduction plans by key shareholders, indicating potential changes in ownership structure and investor sentiment [1] Share Reduction Details - Mr. Shi Huiyong has reduced his holdings by 4.4024 million shares through block trading, while Jinch Investment has reduced its holdings by 2.2048 million shares through centralized bidding [1] - After the completion of the reduction plan, Mr. Shi holds 106 million shares, accounting for 48.27% of the company's total share capital, while Jinch Investment holds 12.0532 million shares, representing 5.47% of the total share capital [1]

Core Viewpoint - The announcement indicates a significant reduction in shareholding by the controlling shareholder and an investment management partnership, which may impact the company's governance and market perception [1] Shareholding Changes - The controlling shareholder, Shi Huiyong, reduced his holdings by 4,402,400 shares, decreasing his ownership from 50.27% to 48.27% [1] - Taizhou Jincheng Investment Management Partnership reduced its holdings by 2,204,840 shares, lowering its stake from 6.47% to 5.47% [1] - Following these transactions, the combined shareholding of Shi Huiyong, Jincheng Investment, and their concerted parties decreased from 63.96% to 61.21%, marking a change that touches the 1% threshold [1]

Core Viewpoint - The stock price of Gongdong Medical (605369) has shown a slight increase, closing at 19.62 yuan, while the company faces challenges with a significant drop in net profit for the third quarter of 2025 compared to the previous year [1][4]. Shareholder Changes - On October 31, Gongdong Medical announced that shareholder Taizhou Jincheng Investment Management Partnership (Limited Partnership) reduced its holdings by 540,200 shares from October 9 to October 30, decreasing its ownership from 6.47% to 6.22% [2][5]. - As of September 30, the number of shareholders reached 11,600, an increase of 1,734 shareholders or 17.57% compared to June 30 [3][6]. Financial Performance - Gongdong Medical's Q3 2025 report indicates a total revenue of 845 million yuan for the first three quarters, reflecting a year-on-year increase of 1.08%. However, the net profit attributable to shareholders dropped by 49.1% to 71.96 million yuan [4][6]. - In Q3 alone, the company reported a revenue of 288 million yuan, up 2.07% year-on-year, but the net profit fell by 53.12% to 21.62 million yuan [4].

Core Viewpoint - Gongdong Medical is a leading manufacturer of disposable medical consumables in China, with advanced production technology and strict quality control systems [1] Group 1: Business Overview - Gongdong Medical was established on August 17, 2009, and was listed on the Shanghai Stock Exchange on September 16, 2020 [1] - The company focuses on the research, production, and sales of disposable medical consumables, categorized under the pharmaceutical and biological industry, specifically in medical devices and consumables [1] Group 2: Financial Performance - For Q3 2025, Gongdong Medical reported revenue of 845 million, ranking 23rd among 50 companies in the industry [2] - The industry leader, Yingke Medical, reported revenue of 7.425 billion, while the second, Guoke Hengtai, reported 5.353 billion; the industry average revenue was 1.379 billion, and the median was 755 million [2] - The company's net profit for the same period was 71.89 million, ranking 29th in the industry [2] - The top net profit earners were Lepu Medical at 999.6 million and Yingke Medical at 952 million, with the industry average at 183 million and the median at 75.88 million [2] Group 3: Financial Ratios - As of Q3 2025, Gongdong Medical's debt-to-asset ratio was 18.49%, an increase from 15.66% year-on-year, which is lower than the industry average of 23.66%, indicating good solvency [3] - The company's gross profit margin for Q3 2025 was 30.13%, down from 33.35% year-on-year, and below the industry average of 48.78%, suggesting a need for improvement in profitability [3] Group 4: Executive Compensation - The chairman, Shi Huiyong, received a salary of 749,000 for 2024, an increase of 68,600 from 2023 [4] - The general manager, Zhong Weifeng, earned 646,900 in 2024, up by 62,300 from the previous year [4] Group 5: Shareholder Information - As of September 30, 2025, the number of A-share shareholders for Gongdong Medical increased by 17.57% to 11,600 [5] - The average number of circulating A-shares held per shareholder decreased by 14.94% to 19,000 [5]

本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： | 权益变动方向 | 比例增加□ | | 比例减少☑ | | --- | --- | --- | --- | | 权益变动前合计比例 | 64.21% | | | | 权益变动后合计比例 | 63.96% | | | | 本次变动是否违反已作出的承诺、 意向、计划 | 是□ | 否☑ | | | 是否触发强制要约收购义务 | 是□ | 否☑ | | 一、 信息披露义务人及其一致行动人的基本信息 1、身份类别 | | ☑控股股东/实际控制人及其一致行动人 | | --- | --- | | | □其他 5%以上大股东及其一致行动人 | | 投资者及其一致行动人的身份 | □合并口径第一大股东及其一致行动人（仅适用于无控 | | | 股股东、实际控制人） | | | □其他______________（请注明） | 证券代码：605369 证券简称：拱东医疗 公告编号：2025-035 浙江拱东医疗器械股份有限公司 关于持股 5%以上股东权益变动触及 1%刻度的 提示性公告 浙江拱东医疗器械股份有限公司（以下简称"公司"、"拱东医 ...